AMG330, a human BiTE (Bispecific T-cell engager) directed against CD33/CD3 led to T-cell expansion (Figure 5E), differentiation, proliferation, and produced a potent T cell cytotoxic response against primary AML blasts, even at low effector to target (E:T) ratios, validating it as a candidate for targeting AML [214]. This evidence concerns the gene CD33 and acute myeloid leukemia.